159 related articles for article (PubMed ID: 38311174)
1. RNA and the RNA-binding protein FUS act in concert to prevent TDP-43 spatial segregation.
Demongin C; Tranier S; Joshi V; Ceschi L; Desforges B; Pastré D; Hamon L
J Biol Chem; 2024 Mar; 300(3):105716. PubMed ID: 38311174
[TBL] [Abstract][Full Text] [Related]
2. TDP-43 and FUS RNA-binding proteins bind distinct sets of cytoplasmic messenger RNAs and differently regulate their post-transcriptional fate in motoneuron-like cells.
Colombrita C; Onesto E; Megiorni F; Pizzuti A; Baralle FE; Buratti E; Silani V; Ratti A
J Biol Chem; 2012 May; 287(19):15635-47. PubMed ID: 22427648
[TBL] [Abstract][Full Text] [Related]
3. TDP-43 and FUS/TLS: cellular functions and implications for neurodegeneration.
Fiesel FC; Kahle PJ
FEBS J; 2011 Oct; 278(19):3550-68. PubMed ID: 21777389
[TBL] [Abstract][Full Text] [Related]
4. TDP-43 and FUS en route from the nucleus to the cytoplasm.
Ederle H; Dormann D
FEBS Lett; 2017 Jun; 591(11):1489-1507. PubMed ID: 28380257
[TBL] [Abstract][Full Text] [Related]
5. How do the RNA-binding proteins TDP-43 and FUS relate to amyotrophic lateral sclerosis and frontotemporal degeneration, and to each other?
Baloh RH
Curr Opin Neurol; 2012 Dec; 25(6):701-7. PubMed ID: 23041957
[TBL] [Abstract][Full Text] [Related]
6. Requirements for stress granule recruitment of fused in sarcoma (FUS) and TAR DNA-binding protein of 43 kDa (TDP-43).
Bentmann E; Neumann M; Tahirovic S; Rodde R; Dormann D; Haass C
J Biol Chem; 2012 Jun; 287(27):23079-94. PubMed ID: 22563080
[TBL] [Abstract][Full Text] [Related]
7. Divergent roles of ALS-linked proteins FUS/TLS and TDP-43 intersect in processing long pre-mRNAs.
Lagier-Tourenne C; Polymenidou M; Hutt KR; Vu AQ; Baughn M; Huelga SC; Clutario KM; Ling SC; Liang TY; Mazur C; Wancewicz E; Kim AS; Watt A; Freier S; Hicks GG; Donohue JP; Shiue L; Bennett CF; Ravits J; Cleveland DW; Yeo GW
Nat Neurosci; 2012 Nov; 15(11):1488-97. PubMed ID: 23023293
[TBL] [Abstract][Full Text] [Related]
8. Amyotrophic lateral sclerosis-associated proteins TDP-43 and FUS/TLS function in a common biochemical complex to co-regulate HDAC6 mRNA.
Kim SH; Shanware NP; Bowler MJ; Tibbetts RS
J Biol Chem; 2010 Oct; 285(44):34097-105. PubMed ID: 20720006
[TBL] [Abstract][Full Text] [Related]
9. Molecular determinants and genetic modifiers of aggregation and toxicity for the ALS disease protein FUS/TLS.
Sun Z; Diaz Z; Fang X; Hart MP; Chesi A; Shorter J; Gitler AD
PLoS Biol; 2011 Apr; 9(4):e1000614. PubMed ID: 21541367
[TBL] [Abstract][Full Text] [Related]
10. Different recognition modes of G-quadruplex RNA between two ALS/FTLD-linked proteins TDP-43 and FUS.
Ishiguro A; Katayama A; Ishihama A
FEBS Lett; 2021 Feb; 595(3):310-323. PubMed ID: 33269497
[TBL] [Abstract][Full Text] [Related]
11. Stress granules in neurodegeneration--lessons learnt from TAR DNA binding protein of 43 kDa and fused in sarcoma.
Bentmann E; Haass C; Dormann D
FEBS J; 2013 Sep; 280(18):4348-70. PubMed ID: 23587065
[TBL] [Abstract][Full Text] [Related]
12. Conjoint pathologic cascades mediated by ALS/FTLD-U linked RNA-binding proteins TDP-43 and FUS.
Ito D; Suzuki N
Neurology; 2011 Oct; 77(17):1636-43. PubMed ID: 21956718
[TBL] [Abstract][Full Text] [Related]
13. Roles of ataxin-2 in pathological cascades mediated by TAR DNA-binding protein 43 (TDP-43) and Fused in Sarcoma (FUS).
Nihei Y; Ito D; Suzuki N
J Biol Chem; 2012 Nov; 287(49):41310-23. PubMed ID: 23048034
[TBL] [Abstract][Full Text] [Related]
14. Oxr1 improves pathogenic cellular features of ALS-associated FUS and TDP-43 mutations.
Finelli MJ; Liu KX; Wu Y; Oliver PL; Davies KE
Hum Mol Genet; 2015 Jun; 24(12):3529-44. PubMed ID: 25792726
[TBL] [Abstract][Full Text] [Related]
15. TDP-43 and FUS/TLS: sending a complex message about messenger RNA in amyotrophic lateral sclerosis?
Strong MJ; Volkening K
FEBS J; 2011 Oct; 278(19):3569-77. PubMed ID: 21810174
[TBL] [Abstract][Full Text] [Related]
16. Hu antigen R (HuR) is a positive regulator of the RNA-binding proteins TDP-43 and FUS/TLS: implications for amyotrophic lateral sclerosis.
Lu L; Zheng L; Si Y; Luo W; Dujardin G; Kwan T; Potochick NR; Thompson SR; Schneider DA; King PH
J Biol Chem; 2014 Nov; 289(46):31792-31804. PubMed ID: 25239623
[TBL] [Abstract][Full Text] [Related]
17. TDP-43/FUS in motor neuron disease: Complexity and challenges.
Guerrero EN; Wang H; Mitra J; Hegde PM; Stowell SE; Liachko NF; Kraemer BC; Garruto RM; Rao KS; Hegde ML
Prog Neurobiol; 2016; 145-146():78-97. PubMed ID: 27693252
[TBL] [Abstract][Full Text] [Related]
18. Understanding the role of TDP-43 and FUS/TLS in ALS and beyond.
Da Cruz S; Cleveland DW
Curr Opin Neurobiol; 2011 Dec; 21(6):904-19. PubMed ID: 21813273
[TBL] [Abstract][Full Text] [Related]
19. Physiological functions and pathobiology of TDP-43 and FUS/TLS proteins.
Ratti A; Buratti E
J Neurochem; 2016 Aug; 138 Suppl 1():95-111. PubMed ID: 27015757
[TBL] [Abstract][Full Text] [Related]
20. Targeting RACK1 to alleviate TDP-43 and FUS proteinopathy-mediated suppression of protein translation and neurodegeneration.
Zhao B; Cowan CM; Coutts JA; Christy DD; Saraph A; Hsueh SCC; Plotkin SS; Mackenzie IR; Kaplan JM; Cashman NR
Acta Neuropathol Commun; 2023 Dec; 11(1):200. PubMed ID: 38111057
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
